Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07811193) titled 'A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Vividion Therapeutics, Inc.
Condition:
Colorectal Adenocarcinoma
Intervention:
Drug: VVD-133214
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 15, 2026
Target Sample Size: 140
Countries of Recruitment...